C4 Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
C4 Therapeutics, Inc. (CCCC) reported Marketable Securities, Unrealized Gain (Loss) of -$372.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-05-12
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$372.00K.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $117.00K, a 86.93% decline year-over-year.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-06-30 was -$73.00K.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-03-31 was -$10.00K.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was -$3.00K, a 101.67% decline from fiscal 2024.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $180.00K, a 95.51% decline from fiscal 2023.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $4.01M.
- C4 Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$3.36M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$372.00K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$3.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $117.00K 10-Q · filed 2025-11-06 | $44.00K derived: sum of 2 quarters · filed 2025-11-06 | $34.00K derived: sum of 3 quarters · filed 2026-05-12 | -$368.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-06-30 | -$73.00K 10-Q · filed 2025-11-06 | -$83.00K 10-Q · filed 2025-08-07 | -$485.00K derived: sum of 3 quarters · filed 2026-05-12 | $410.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-03-31 | -$10.00K 10-Q · filed 2026-05-12 | -$412.00K derived: sum of 2 quarters · filed 2026-05-12 | $483.00K derived: sum of 3 quarters · filed 2026-05-12 | $423.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $493.00K derived: sum of 2 quarters · filed 2026-02-26 | $433.00K derived: sum of 3 quarters · filed 2026-02-26 | $180.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $895.00K 10-Q · filed 2025-11-06 | $835.00K derived: sum of 2 quarters · filed 2025-11-06 | $582.00K 10-Q · filed 2024-10-31 | $1.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$60.00K 10-Q · filed 2025-11-06 | -$313.00K 10-Q · filed 2025-08-07 | $464.00K derived: sum of 3 quarters · filed 2025-11-06 | $1.33M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$253.00K 10-Q · filed 2025-11-06 | $524.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.39M derived: sum of 3 quarters · filed 2025-11-06 | $2.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $777.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.65M derived: sum of 2 quarters · filed 2025-02-27 | $2.34M derived: sum of 3 quarters · filed 2025-02-27 | $4.01M 10-K · filed 2025-02-27 |
| 2023-09-30 | $870.00K 10-Q · filed 2024-10-31 | $1.57M derived: sum of 2 quarters · filed 2024-10-31 | $3.23M 10-Q · filed 2024-10-31 | $4.50M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $696.00K 10-Q · filed 2024-10-31 | $2.36M 10-Q · filed 2024-08-01 | $3.63M derived: sum of 3 quarters · filed 2024-10-31 | $2.81M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-10-31 | $2.94M derived: sum of 2 quarters · filed 2024-10-31 | $2.11M derived: sum of 3 quarters · filed 2024-10-31 | $1.18M derived: sum of 4 quarters · filed 2024-10-31 |
| 2022-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $444.00K derived: sum of 2 quarters · filed 2024-02-22 | -$487.00K derived: sum of 3 quarters · filed 2024-02-22 | -$3.36M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$828.00K 10-Q · filed 2023-11-01 | -$1.76M derived: sum of 2 quarters · filed 2023-11-01 | -$4.63M 10-Q · filed 2023-11-01 | -$5.25M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$931.00K 10-Q · filed 2023-11-01 | -$3.81M 10-Q · filed 2023-08-08 | -$4.43M derived: sum of 3 quarters · filed 2023-11-01 | -$4.51M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-03-31 | -$2.88M 10-Q · filed 2023-11-01 | -$3.50M derived: sum of 2 quarters · filed 2023-11-01 | -$3.58M derived: sum of 3 quarters · filed 2023-11-01 | -$3.56M derived: sum of 4 quarters · filed 2023-11-01 |
| 2021-12-31 | -$620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$706.00K derived: sum of 2 quarters · filed 2023-02-23 | -$681.00K derived: sum of 3 quarters · filed 2023-02-23 | -$788.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | -$86.00K 10-Q · filed 2022-11-03 | -$61.00K derived: sum of 2 quarters · filed 2022-11-03 | -$168.00K 10-Q · filed 2022-11-03 | -$163.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $25.00K 10-Q · filed 2022-11-03 | -$82.00K 10-Q · filed 2022-08-04 | -$77.00K derived: sum of 3 quarters · filed 2022-11-03 | -$67.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-03-31 | -$107.00K 10-Q · filed 2022-11-03 | -$102.00K derived: sum of 2 quarters · filed 2022-11-03 | -$92.00K derived: sum of 3 quarters · filed 2022-11-03 | -$94.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2020-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $15.00K derived: sum of 2 quarters · filed 2022-02-24 | $13.00K derived: sum of 3 quarters · filed 2022-02-24 | $13.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $10.00K 10-Q · filed 2021-11-10 | $8.00K derived: sum of 2 quarters · filed 2021-11-10 | $8.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.00K 10-Q · filed 2021-11-10 | -$2.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |